PsychoGenics Inc. has launched eCube, a pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery.
The company says that unlike traditional target-based drug discovery, this technique can identify new treatments with multiple targets.
Similar to the company’s AI-enabled behavior-based platform SmartCube, eCube leverages machine learning to identify central nervous system (CNS) penetrant compounds and predict their therapeutic applications for neuropsychiatric disorders by comparing their EEG profiles with a pharmacoEEG database consisting of hundreds of doses of active-reference drugs. SSP.
eCube measures drug-induced changes in EEG spectral data and uses machine learning classifiers that are trained on reference drugs to predict the efficacy of new compounds at the drug class (primary therapeutic indication) and subclass (primary mechanism of action) levels.
In addition to predicting therapeutic applications for new compounds, eCube can transmit translational biomarkers, providing an objective means of assessing CNS activity, which is especially important for compounds with unknown or complex mechanisms of action.
“The eCube platform joins an innovative class of AI-enabled phenotypic platforms from PsychoGenics, including SmartCube, which has helped advance many compounds to clinical trials, including Ulotaront. Discovered in partnership with Sunovion, Ulotaront is now in phase 3 for schizophrenia, as well as generalized depression and anxiety disorders,” said Emer Leahy, CEO, PsychoGenics.
“The eCube is another important discovery tool that is helping to provide new treatments to patients suffering from very disabling conditions.”
“The introduction of eCube provides a truly unique translational tool for target-agnostic compound screening and prospecting. Our reference EEG database and analytical machine learning tools not only allow us to predict therapeutic efficacy, but also to quantify the similarity of EEG spectra to other CNS drugs,” added Dani Brunner, chief innovation officer, PsychoGenics.
“This robust platform can confirm therapeutic predictions from our behavior-based platform, identify neural circuits, and provide translational biomarkers to support clinical development.”
PsychoGenics Inc. and its discovery unit, PGI Drug Discovery LLC, have pioneered the translation of rodent physiological and behavioral responses into robust, high-throughput, high-content phenotypes. The PsychoGenics drug discovery platforms SmartCube, NeuroCube, and PhenoCube have been used in joint risk partnerships with pharmaceutical companies including Sunovion, Roche and Karuna, resulting in the discovery of several new compounds that are now in clinical trials or advanced preclinical development.
PsychoGenics capabilities also include standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis and quantitative immunohistochemistry, and, now, eCube. The company also offers licensed transgenic mouse models that support research in areas such as Huntington’s disease, autism spectrum disorder, psychosis/schizophrenia, depression, PTSD, Alzheimer’s disease, Parkinson’s disease, muscular dystrophy, ALS, and seizure disorders.
PsychoGenics was featured recently in a Labiotech feature about women in biotech.